Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two drugs, sibutramine and clarithromycin. Sibutramine is a centrally-acting appetite suppressant formerly used for weight loss and obesity management; it works primarily by inhibiting the reuptake of serotonin, norepinephrine, and dopamine in the brain. Clarithromycin is a macrolide antibiotic used to treat various bacterial infections by inhibiting protein synthesis in susceptible bacteria. When administered together, clarithromycin can significantly increase plasma concentrations of sibutramine due to inhibition of hepatic metabolism (notably CYP3A4), potentially raising the risk of adverse effects associated with sibutramine[1][4][5][8]. This combination does not have an established therapeutic indication as a fixed product; co-administration may occur incidentally or during drug interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sibutramine + clarithromycin.